Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP,Strategy/Corp Development | May 27, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 27, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 98,611 |
Reported balance
After 2026-05-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-27 · Sale · Disposed 23,145 · Balance 98,611 F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 22,798.2532 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 22,798.2532 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 30,969.5756 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 30,969.5756 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2020 Filed Apr 3, 2020 22:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,369 | $182.44 | $979,520.36 |
DisclosureSEC source: 0001225208-20-006081 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,821.5169 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| April 03, 2020 Filed Apr 3, 2020 22:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,369 | $35.79 | $192,129.67 |
DisclosureSEC source: 0001225208-20-006081 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,190.5169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,369 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-20-004647 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,741 Underlying: Common Stock · 5,369 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,369 | $201.90 | $1,084,001.10 |
DisclosureSEC source: 0001225208-20-004647 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,712.9683 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,369 | $35.79 | $192,129.67 |
DisclosureSEC source: 0001225208-20-004647 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,081.9683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| February 07, 2020 Filed Feb 7, 2020 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,369 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-20-001849 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,110 Underlying: Common Stock · 5,369 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| February 07, 2020 Filed Feb 7, 2020 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,369 | $235.65 | $1,265,204.85 |
DisclosureSEC source: 0001225208-20-001849 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,712.9683 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| February 07, 2020 Filed Feb 7, 2020 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,369 | $35.79 | $192,129.67 |
DisclosureSEC source: 0001225208-20-001849 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,081.9683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| January 10, 2020 Filed Jan 10, 2020 23:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,369 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-20-000718 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,479 Underlying: Common Stock · 5,369 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| January 10, 2020 Filed Jan 10, 2020 23:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,369 | $235.69 | $1,265,419.61 |
DisclosureSEC source: 0001225208-20-000718 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,712.9683 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| January 10, 2020 Filed Jan 10, 2020 23:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,369 | $35.79 | $192,129.67 |
DisclosureSEC source: 0001225208-20-000718 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,081.9683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,369 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-015636 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,848 Underlying: Common Stock · 5,369 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,369 | $229.26 | $1,230,896.94 |
DisclosureSEC source: 0001225208-19-015636 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,712.9683 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,369 | $35.79 | $192,129.67 |
DisclosureSEC source: 0001225208-19-015636 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,081.9683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| November 08, 2019 Filed Nov 8, 2019 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,369 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-014314 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,217 Underlying: Common Stock · 5,369 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| November 08, 2019 Filed Nov 8, 2019 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,369 | $234.37 | $1,258,332.53 |
DisclosureSEC source: 0001225208-19-014314 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,712.9683 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| November 08, 2019 Filed Nov 8, 2019 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,369 | $35.79 | $192,129.67 |
DisclosureSEC source: 0001225208-19-014314 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,081.9683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| November 06, 2019 Filed Nov 6, 2019 22:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 10,500 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-014204 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,300 Underlying: Common Stock · 10,500 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2019 Filed Nov 6, 2019 22:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,000 | $234.52 | $1,876,182.40 |
DisclosureSEC source: 0001225208-19-014204 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,712.9683 F2 · price: This transaction was executed in multiple trades at prices ranging from $233.80 to $234.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2019 Filed Nov 6, 2019 22:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $234.88 | $587,198.75 |
DisclosureSEC source: 0001225208-19-014204 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,712.9683 F1 · price: This transaction was executed in multiple trades at prices ranging from $234.80 to $235.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2019 Filed Nov 6, 2019 22:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,500 | $41.94 | $440,370.00 |
DisclosureSEC source: 0001225208-19-014204 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,212.9683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2019 Filed Oct 4, 2019 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,369 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-013207 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,586 Underlying: Common Stock · 5,369 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| October 04, 2019 Filed Oct 4, 2019 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,369 | $223.18 | $1,198,253.42 |
DisclosureSEC source: 0001225208-19-013207 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,712.9683 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| October 04, 2019 Filed Oct 4, 2019 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,369 | $35.79 | $192,129.67 |
DisclosureSEC source: 0001225208-19-013207 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,081.9683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| September 06, 2019 Filed Sep 6, 2019 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,369 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-012225 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,955 Underlying: Common Stock · 5,369 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| September 06, 2019 Filed Sep 6, 2019 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,369 | $226.26 | $1,214,789.94 |
DisclosureSEC source: 0001225208-19-012225 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,712.9683 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| September 06, 2019 Filed Sep 6, 2019 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,369 | $35.79 | $192,129.67 |
DisclosureSEC source: 0001225208-19-012225 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,081.9683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| August 09, 2019 Filed Aug 9, 2019 18:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,369 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-011114 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,324 Underlying: Common Stock · 5,369 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| August 09, 2019 Filed Aug 9, 2019 18:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,369 | $216.26 | $1,161,099.94 |
DisclosureSEC source: 0001225208-19-011114 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,712.9683 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| August 09, 2019 Filed Aug 9, 2019 18:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,369 | $35.79 | $192,129.67 |
DisclosureSEC source: 0001225208-19-011114 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,081.9683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 18:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-011114 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 41,232 Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 21,000 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-010722 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,800 Underlying: Common Stock · 21,000 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,730 | $211.50 | $2,692,363.18 |
DisclosureSEC source: 0001225208-19-010722 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,712.9683 F2 · price: This transaction was executed in multiple trades at prices ranging from $211.0900 to $212.0875. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,270 | $212.56 | $1,757,897.66 |
DisclosureSEC source: 0001225208-19-010722 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,442.9683 F1 · price: This transaction was executed in multiple trades at prices ranging from $212.1100 to $212.8300. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 21,000 | $41.94 | $880,740.00 |
DisclosureSEC source: 0001225208-19-010722 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,712.9683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2019 Filed Jul 10, 2019 21:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,369 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-010177 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,693 Underlying: Common Stock · 5,369 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| July 10, 2019 Filed Jul 10, 2019 21:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,369 | $190.09 | $1,020,593.21 |
DisclosureSEC source: 0001225208-19-010177 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,712.9683 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| July 10, 2019 Filed Jul 10, 2019 21:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,369 | $35.79 | $192,129.67 |
DisclosureSEC source: 0001225208-19-010177 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,081.9683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 22:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,369 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-009277 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,062 Underlying: Common Stock · 5,369 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 22:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,369 | $184.55 | $990,848.95 |
DisclosureSEC source: 0001225208-19-009277 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,674.3275 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 22:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,369 | $35.79 | $192,129.67 |
DisclosureSEC source: 0001225208-19-009277 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,043.3275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 30, 2019 Filed May 30, 2019 22:14 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,000 | $169.60 | $508,789.80 |
DisclosureSEC source: 0001225208-19-008644 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 43,832 F1 · price: This transaction was executed in multiple trades at prices ranging from $169.17 to $170.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 17, 2019 Filed May 17, 2019 21:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,369 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-008185 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,431 Underlying: Common Stock · 5,369 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 17, 2019 Filed May 17, 2019 21:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,369 | $175.06 | $939,897.14 |
DisclosureSEC source: 0001225208-19-008185 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,674.3275 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 17, 2019 Filed May 17, 2019 21:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,369 | $35.79 | $192,129.67 |
DisclosureSEC source: 0001225208-19-008185 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,043.3275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 14, 2019 Filed May 14, 2019 22:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,078 | $178.17 | $192,067.26 |
DisclosureSEC source: 0001225208-19-007992 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,674.3275 Read SEC document |
| May 12, 2019 Filed May 14, 2019 22:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007992 · doc4.xml · derivative · entry 8 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,784 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.exercise_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.expiration_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.underlying_shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 14, 2019 22:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,381 | $181.10 | $250,099.10 |
DisclosureSEC source: 0001225208-19-007992 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,752.3275 F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 14, 2019 22:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 691 | $181.10 | $125,140.10 |
DisclosureSEC source: 0001225208-19-007992 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,133.3275 Read SEC document |
| May 12, 2019 Filed May 14, 2019 22:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007992 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,824.3275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.